阿托伐他汀对急性脑出血患者血浆炎性因子的影响及疗效观察

Observation of the influence of atorvastatin on inflammatory cytokines in plasma of patients with acute hemorrhage o brain and the effect

目的:探讨阿托伐他汀对急性脑出血患者血浆炎性因子的影响及临床疗效。方法:2013年2月-2014年7月收治急性脑出血患者60例,随机分成观察组和对照组各30例,对照组给予控制血压、血糖,降低颅内压,营养脑细胞的原则进行治疗。观察组在对照组的基础上加阿托伐他汀20 mg/次,1次/d,均连续治疗2周,观察TNF-α和hs-CRP治疗前后的变化。结果:观察组治疗前TNF-α(44.1±14.2)μg/L,hs-CRP(11.0±3.1)mg/L,治疗后TNF-α(20.1±7.4)μg/L,hs-CRP(4.8±1.1)mg/L;对照组治疗前TNF-α(44.0±14.1)μg/L,hs-CRP(10.9±3.0)mg/L,治疗后TNF-α(32.6±14.8)μg/L,hs-CRP(7.8±2.1)mg/L;两组患者治疗前TNF-α和hs-CRP比较差异无统计学意义(P>0.05),治疗后与治疗前比较有统计学意义(P<0.05),两组治疗后比较有统计学意义(P<0.05);观察组总有效率96.7%,对照组总有效率84.3%,两组比较差异有统计学意义(P<0.05)。结论:阿托伐他汀可以明显降低炎性因子的影响,提高临床疗效,值得推广。

Objective:To explore the influence of atorvastatin on inflammatory cytokines in plasma of patients with acute hemorrhage of brain and the effect.Methods:60 patients with acute cerebral hemorrhage were selected from February 2013 to July2014.They were randomly divided into the observation group and the control group with 30 cases in each group.The control group were given control of blood pressure and blood sugar,reducing intracranial pressure,brain cell nutrition therapy.The observation group were given atorvastatin 20 mg/time on the basis of the control group,1 time /day,continuously for 2 weeks.We observed the changes of TNF-α and hs-CRP before and after treatment.Results:In the observation group,before treatment,TNF-α was(44.1±14.2)μg/L,and hs-CRP was(11±3.1)mg/L;after treatment,TNF-α was(20.1±7.4)μg/L,and hs-CRP was(4.8±1.1)mg/L.In the control group,before treatment,TNF-α was(44 ± 14.1) μ g/L,and hs-CRP) was(10.9 ± 3)mg/L;after treatment,TNF-α was(32.6±14.8)μg/L,and hs-CRP was(7.8±2.1)mg/L.Compared the two groups of patients before treatment with TNF-α and hs-CRP,there was no significant difference(P>0.05);compared before and after treatment,the difference was statistically significant(P<0.05);compared the two groups after treatment,the difference was statistically significant(P<0.05).In the observation group,the total efficiency was 96.7%;in the control group,the total efficiency was 84.3%;the difference was statistically significant(P<0.05).Conclusion:Atorvastatin can significantly reduce the influence of inflammatory factors and improve the clinical efficacy,and it is worthy of promotion.